Pacritinib May Benefit Patients with Myelofibrosis and Thrombocytopenia

Data recently published from the phase III PERSIST-2 trial shows that the oral JAK2/FLT inhibitor pacritinib demonstrates a higher reduction in spleen volume and in total symptom score in patients with myelofibrosis and thrombocytopenia compared with best available therapy.

 Cancer Network

By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.